1793052-96-6

1793052-96-6 structure

Name: SRS16-86
Chemical Name: SRS16-86
CAS Number: 1793052-96-6
Molecular Formula: C₂₆H₃₂N₄O₂
Molecular Weight: 432.558
Catalog: Signaling Pathways Apoptosis Ferroptosis
Create Date: 2021-01-08 17:39:23
Modify Date: 2024-01-12 10:47:31
SRS16-86 is a potent inhibitor of ferroptosis[1]. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research[2][3].

Name	SRS16-86
Synonyms	Benzoic acid, 3-[[(1Z)-5-pyrimidinylmethylene]amino]-4-(tricyclo[3.3.1.13,7]dec-1-ylamino)-, 1,1-dimethylethyl ester 2-Methyl-2-propanyl 4-[(3s,5s,7s)-adamantan-1-ylamino]-3-[(Z)-(5-pyrimidinylmethylene)amino]benzoate SRS16-86

Description	SRS16-86 is a potent inhibitor of ferroptosis[1]. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research[2][3].
Related Catalog	Signaling Pathways >> Apoptosis >> Ferroptosis Research Areas >> Inflammation/Immunology
In Vitro	SRS16-86 (1 µM; 24 hours; in the presence or absence of erastin) inhibits ferroptosis in HT-1080 cells and NIH 3T3 cells[2].
In Vivo	SRS16-86 (intraperitoneal injection; 2 mg/kg; 15 min before the onset of surgery) protects mice from functional acute renal failure and structural organ damage after ischemia–reperfusion injury (IRI)[2]. SRS16-86 (intraperitoneal injection; 2 mg/kg; 4 weeks) combination therapy with [Nec-1+SfA] is superior in the prevention of renal IRI compared with the double-combination therapy with [Nec-1+SfA]. Addition of 16-86 reduces plasma levels of serum urea and serum creatinine in IRI mice model[2]. SRS16-86 (intraperitoneal injection; 15 mg/kg; once a day; 7 days) enhances functional recovery after SCI, it decreases the levels of proinflammatory cytokines and the inflammatory adhesion factor in injured spinal cord in rats[3]. Animal Model: Renal IRI model Dosage: 2 mg/kg; 15 min before the onset of surgery Administration: Intraperitoneal injection; 2 mg/kg; 15 min before the onset of surgery Result: Was protective from renal IRI. Animal Model: Renal IRI model Dosage: 2 mg/kg Administration: Combination with Necrostatin-1/Sanglifehrin A; 2 mg/kg; 4 weeks Result: Further increased the protective effect of [Necrostatin-1/Sanglifehrin A] combination therapy in renal IRI model.
References	[1]. Sam Hofmans, et al. Novel Ferroptosis Inhibitors with Improved Potency and ADME Properties. J Med Chem. 2016 Mar 10;59(5):2041-53. [2]. Andreas Linkermann, et al. Synchronized renal tubular cell death involves ferroptosis.Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16836-41. [3]. Yan Zhang, et al. Ferroptosis inhibitor SRS 16-86 attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury. Brain Res. 2019 Mar 1;1706:48-57.

Density	1.3±0.1 g/cm3
Boiling Point	614.9±55.0 °C at 760 mmHg
Molecular Formula	C₂₆H₃₂N₄O₂
Molecular Weight	432.558
Flash Point	325.7±31.5 °C
Exact Mass	432.252533
LogP	4.93
Vapour Pressure	0.0±1.8 mmHg at 25°C
Index of Refraction	1.656

1793052-96-6	247085-49-0
15743-56-3	1357349-91-7
14932-53-7	75478-98-7
1150586-64-3	13982-14-4
1802392-86-4	648881-58-7